Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06039826 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT06039826 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 46 participants.
The verdict
NCT06039826, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerability of LY3437943 when administered with COC will also be evaluated. This study will last up to approximately 29 weeks for each participant.
Interventions
- DRUG LY3437943
- DRUG Drospirenone
- DRUG Ethinyl Estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-09-12 |
| Est. Completion | 2024-07-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06039826
The ClinicalTrials.gov registry entry for NCT06039826 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LY3437943 is the first listed.
NCT06039826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06039826 about?
NCT06039826 is a clinical study titled "A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese". The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerabi...
What is the current status of trial NCT06039826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2023-09-12. Estimated completion is 2024-07-11.
What interventions are being tested in trial NCT06039826?
The interventions under investigation include: LY3437943 (DRUG), Drospirenone (DRUG), Ethinyl Estradiol (DRUG).
Who is sponsoring clinical trial NCT06039826?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.